Here is the opening:
Even as Americans heatedly argue the issue of free speech with respect to cartoon criticisms of Islam, the small drug company Amarin is striking a quieter blow for its free speech rights against the Food and Drug Adminstration (FDA).Of course, drug companies should not be allowed to disseminate false or misleading information about their products. That can and should be punished as fraud.
The key issue is whether drug companies can tell doctors truthful information about their products that pertains to “off-label” uses (i.e., for applications not already explicitly approved by the FDA.)
But both doctors and patients benefit when drug companies are allowed to publish truthful information.
Bonus infographic on the onerous FDA approval process!
